Schonfeld Strategic Advisors LLC Purchases Shares of 36,180 Verastem, Inc. (NASDAQ:VSTM)

Schonfeld Strategic Advisors LLC bought a new stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 36,180 shares of the biopharmaceutical company's stock, valued at approximately $187,000. Schonfeld Strategic Advisors LLC owned about 0.08% of Verastem as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stifel Financial Corp grew its position in Verastem by 30.5% in the fourth quarter. Stifel Financial Corp now owns 39,593 shares of the biopharmaceutical company's stock valued at $205,000 after acquiring an additional 9,254 shares during the last quarter. Rhumbline Advisers grew its position in Verastem by 38.0% in the fourth quarter. Rhumbline Advisers now owns 37,629 shares of the biopharmaceutical company's stock valued at $195,000 after acquiring an additional 10,352 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Verastem by 41.3% during the fourth quarter. Wells Fargo & Company MN now owns 20,571 shares of the biopharmaceutical company's stock worth $106,000 after purchasing an additional 6,012 shares during the last quarter. Voya Investment Management LLC bought a new stake in shares of Verastem during the fourth quarter worth about $59,000. Finally, Barclays PLC grew its holdings in shares of Verastem by 546.7% during the third quarter. Barclays PLC now owns 55,708 shares of the biopharmaceutical company's stock worth $167,000 after purchasing an additional 47,094 shares during the last quarter. Institutional investors own 88.37% of the company's stock.

Verastem Trading Up 2.1%

VSTM stock traded up $0.16 during trading on Monday, hitting $7.75. The company had a trading volume of 1,176,255 shares, compared to its average volume of 1,112,206. The business has a 50-day moving average of $6.42 and a 200-day moving average of $5.64. Verastem, Inc. has a one year low of $2.10 and a one year high of $12.45. The stock has a market cap of $425.85 million, a PE ratio of -2.43 and a beta of 0.85. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77.

Verastem (NASDAQ:VSTM - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24). Research analysts predict that Verastem, Inc. will post -3.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. B. Riley boosted their price target on Verastem from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Mizuho reduced their price target on Verastem from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. StockNews.com cut Verastem from a "hold" rating to a "sell" rating in a report on Friday, April 18th. Royal Bank of Canada reduced their price target on Verastem from $16.00 to $14.00 and set an "outperform" rating on the stock in a report on Friday, March 21st. Finally, HC Wainwright boosted their price target on Verastem from $10.00 to $14.00 and gave the stock a "buy" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $14.33.

Verastem Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.